4 completed, 2 terminated, 2 withdrawn, 1 no longer available. 7 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow glembatumumab vedotin: new trials by email Literature Review of glembatumumab vedotin trials Research Report on glembatumumab vedotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer Glembatumumab Vedotin - Triple Negative Breast Cancer | Early Phase 1 | Withdrawn | University of Virginia | 2018-05-01 | 2024-12-09 | |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Phase I: Glembatumumab Vedotin, Phase II: Glembatumumab Vedotin - Squamous Cell Carcinoma of the Lung | Phase 1 / Phase 2 | Terminated | PrECOG, LLC. | 13 | 2016-04-10 | 2019-07-16 |
| Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Osteosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2016-02-16 | 2022-01-18 |
| Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2015-09-16 | 2020-08-21 |
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab) - Melanoma | Phase 2 | Terminated | Celldex Therapeutics | 132 | 2014-11-01 | 2019-09-06 |
| Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer CDX-011, Capecitabine - Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | Phase 2 | Completed | Celldex Therapeutics | 327 | 2013-11-01 | 2019-03-08 |
| A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer CDX-011, "Investigator's Choice" chemotherapy - Breast Cancer | Phase 2 | Completed | Celldex Therapeutics | 120 | 2010-07-01 | 2017-07-02 |
| Individual Patient Expanded Access-Glembatumumab Vedotin glembatumumab vedotin - Metastatic gpNMB Expressing Triple Negative Breast Cancer | No longer available | Celldex Therapeutics | 2018-05-21 |
Breast Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Melanoma (2) · Uveal Melanoma (2) · Neoplasm Metastasis (1) · Osteosarcoma (1) · Skin Neoplasms (1)
Celldex Therapeutics (4) · National Cancer Institute (NCI) (3) · PrECOG, LLC. (1) · University of Virginia (1)
United States (6) · Canada (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Haeseong Park (1) · Lisa M Kopp (1) · Patrick Dillon, MD (1) · Rathi Pillai, MD (1) · Sapna Patel (1)
N01CM00039 (1), U10CA180886 (1), UM1CA186704 (1), UM1CA186712 (1)